Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to develop new treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. The Company is co-founded by pioneers in the field of CAR-based immunotherapy, nucleic acid drug delivery, tLNPs, and regenerative medicine, including experienced industry leaders, as well as academic faculty members from the University of Pennsylvania.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/14/22 | $165,000,000 | Seed and Series A |
Alexandria Venture Investments Bristol Myers Squibb Eli Lilly and Company Leaps by Bayer Novartis Venture Funds OrbiMed Advisors Pfizer Venture Investments  Polaris Partners RA Capital Management Vida Ventures | undisclosed |
